Undeterred by gene therapy’s struggles, a startup launches into a downturn

Gene therapy companies have been especially vulnerable to a public market downturn that’s shaken the biotech sector. But the difficult environment hasn’t stopped venture firms from betting on the science, as evidenced by the launch of a startup on Tuesday that’s raised up to $67 million in early funding.